Carbidopa/ONO-2160

N/A

Report date: 2024/11/29 15:12:16

Base Information

Drug NameCarbidopa/ONO-2160
Drug Alias NameLevodopa prodrug+carbidopaLevodopa prodrug/carbidopaCarbidopa+ONO-2160Carbidopa+levodopa prodrugCarbidopa/levodopa prodrug
ClassificationSmall molecules
Mechanisms of ActionDOPA decarboxylase inhibitorsDopamine receptors agonists
TargetsAromatic-L-amino-acid decarboxylaseDopamine receptors
Therapy Area/IndicationsParkinson Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsYes ONO-2160Carbidopa
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesOno Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesOno Pharmaceutical Co Ltd
Active IndicationsN/A
Inactive IndicationsParkinson Disease

Other Information

ATC CodeN/A
Related LinksN/A